Zydus Pharmaceuticals Revenue and Competitors

Pennington, NJ USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Zydus Pharmaceuticals's estimated annual revenue is currently $56.3M per year.(i)
  • Zydus Pharmaceuticals's estimated revenue per employee is $201,000

Employee Data

  • Zydus Pharmaceuticals has 280 Employees.(i)
  • Zydus Pharmaceuticals grew their employee count by 22% last year.

Zydus Pharmaceuticals's People

NameTitleEmail/Phone
1
Associate VP, Marketing and Product ManagementReveal Email/Phone
2
Associate VP, National AccountsReveal Email/Phone
3
SVP - Injectables BusinessReveal Email/Phone
4
Head ITReveal Email/Phone
5
AVP Supply Chain & LogisticsReveal Email/Phone
6
Director, National AccountsReveal Email/Phone
7
Senior Director, Human Resources & AdministrationReveal Email/Phone
8
General Counsel & Compliance OfficerReveal Email/Phone
9
Director National Account at Zydus Pharmaceuticals USA, Inc.Reveal Email/Phone
10
Sr. Director, Head U.S. Animal HealthReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M25-11%N/AN/A
#2
$35.8M1788%N/AN/A
#3
$5.4M27-25%N/AN/A
#4
$4180M145161%$550MN/A
#5
$12.5M6215%N/AN/A
#6
$6.7M119-37%$199.6MN/A
#7
$9.4M477%N/AN/A
#8
$10.3M516%N/AN/A
#9
$106.3M52916%N/AN/A
#10
$15.5M7720%N/AN/A
Add Company

What Is Zydus Pharmaceuticals?

Company Overview Zydus Pharmaceuticals (USA) Inc. is a globally integrated generic pharmaceutical company with a focus on providing high service, quality and affordable products. Our leadership, which has over 50 years of US generic market experience, understands our customer's business which allows Zydus Pharmaceuticals the ability to provide unique models to help drive their success. Though a relatively new company in the US market, our parent Zydus Cadila has a large presence in the global markets, including relationships with many top tier international pharmaceutical companies. Based on a manufacturing and development history that spans over 55 years, our experience and knowledge affords us the ability to have one of the largest and most aggressive DMF and finished product pipelines in the industry. Over the next three years we will be filing on average two additional products and DMFs per month. Through 2007 we will exceed that goal by filing over 70 products and 60 DMFs. We are capable to support that growth with the largest, state-of-the-art, cGMP, FDA approved formulation plant in India boasting a capacity near 12 billion units. We also have two FDA approved API plants with capacities exceeding 280 metric tons. Our sustained release technology and ability to manufacture tablet, capsule, soft gel, sterile liquids, injectables, inhalers, topicals and trans-dermal patch dosage forms allows us to target even the most difficult of products. Once manufactured, our packaging area is equipped to handle special customer requests such as bulk, unit-of-use, blister, and child-resistant consumer product packaging. Zydus Pharmaceuticals (USA) Inc. is located in Pennington, New Jersey. To learn more, please contact us through this website or call (609)730-1900.

keywords:N/A

N/A

Total Funding

280

Number of Employees

$56.3M

Revenue (est)

22%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Zydus Pharmaceuticals News

2022-04-19 - Global Azathioprine Tablets Market 2022 Product Analysis ...

Mylan; Zydus Pharmaceuticals; Amneal Pharmaceuticals; Teva; Sinepharm; Beijing Jialin Pharmaceutical. The market is fragmented into the...

2022-04-19 - Global Anastrozole Tablets Market 2022 Business Strategies ...

Zydus Pharmaceuticals; Teva; Hikma Pharmaceuticals; Natco Pharma; Fresenius Kabi; Accord Healthcare; Mylan; Cipla; Apotex; HISUN; Chongqing...

2022-04-17 - Pricing pressures, high raw material costs could cast damper on Q4 pharma earnings

Nomura said companies whose earnings could disappoint the least were Torrent Pharma, Gland Pharma, Zydus Lifesciences and Dr Lal Pathlabs.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$70.1M3741%N/A
#2
$15960M421N/AN/A
#3
$104M462N/AN/A
#4
$111.6M4962%N/A